{"id":"NCT02345850","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","briefTitle":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","officialTitle":"A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301; Progress II)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2020-10-05","completion":"2020-10-05","firstPosted":"2015-01-26","resultsPosted":"2021-12-21","lastUpdate":"2023-03-07"},"enrollment":346,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Acute Leukemia","Myelodysplasia"],"interventions":[{"type":"PROCEDURE","name":"Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate","otherNames":[]},{"type":"PROCEDURE","name":"Mobilized CD34-selected Peripheral Blood Stem Cell graft","otherNames":[]},{"type":"PROCEDURE","name":"Unmanipulated Bone Marrow Graft with Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Cytoxan®"]},{"type":"DRUG","name":"Tacrolimus","otherNames":["Prograf®","FK506"]},{"type":"DRUG","name":"Methotrexate","otherNames":["MTX"]}],"arms":[{"label":"Tacrolimus/Methotrexate Control Arm","type":"ACTIVE_COMPARATOR"},{"label":"CD34 Selection Arm","type":"EXPERIMENTAL"},{"label":"Post Transplant Cyclophosphamide","type":"EXPERIMENTAL"}],"summary":"The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies undergoing myeloablative conditioning hematopoietic stem cell transplantation.","primaryOutcome":{"measure":"Chronic GVHD-free, Relapse-free Survival (CRFS) Probability","timeFrame":"2 years","effectByArm":[{"arm":"CD34 Selected Graft","deltaMin":60.2,"sd":null},{"arm":"Post-Transplant Cyclophosphamide","deltaMin":60.3,"sd":null},{"arm":"Tacrolimus/Methotrexate Control","deltaMin":52.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.2368"},{"comp":"OG001 vs OG002","p":"0.4134"},{"comp":"OG000 vs OG001","p":"0.7166"},{"comp":"OG000 vs OG001 vs OG002","p":"0.386"},{"comp":"OG000 vs OG001 vs OG002","p":"0.461"},{"comp":"OG000 vs OG001 vs OG002","p":"0.115"},{"comp":"OG000 vs OG001 vs OG002","p":"0.227"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":28,"countries":["United States"]},"refs":{"pmids":["34855460","33811823"],"seeAlso":["https://bethematch.org/"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":114},"commonTop":["FOLLICULAR LYMPHOMA","RESPIRATORY FAILURE","ARTHRALGIA","ELEVATED ENDOTOXIN LEVEL","PLATELET COUNT DECREASE"]}}